▁British 8.59375
▁Bi 8.046875
ote 1.81640625
ch 0.12213134765625
' 5.16796875
s 0.00858306884765625
▁Can 5.8984375
cer 0.04095458984375
▁D 1.435546875
rug 0.01163482666015625
▁Sh 3.03515625
ows 0.058746337890625
▁Promise 0.8701171875
, 3.509765625
▁But 1.478515625
▁Anal 5.65234375
yst 0.00507354736328125
s 0.2244873046875
▁Ur 4.67578125
ge 0.00576019287109375
▁Ca 0.18701171875
ution 0.00024330615997314453
<0x0A> 0.11065673828125
L 4.9140625
ON 0.31884765625
D 0.0002560615539550781
ON 0.0001913309097290039
▁- 3.541015625
▁In 4.2109375
▁a 1.0087890625
▁break 3.970703125
through 0.0369873046875
▁development 5.0546875
, 1.580078125
▁British 1.1953125
▁bi 0.3681640625
ote 0.02215576171875
ch 0.335693359375
▁firm 1.044921875
▁Med 4.25
Gen 8.8203125
▁has 5.734375
▁reported 3.1328125
▁encourag 2.76953125
ing 0.0006160736083984375
▁results 0.494384765625
▁for 1.9794921875
▁its 0.51806640625
▁experimental 1.3447265625
▁cancer 0.64404296875
▁drug 0.308349609375
, 1.0205078125
▁M 2.630859375
G 1.14453125
X 4.0703125
- 0.8974609375
1 0.90673828125
5 2.388671875
0 1.708984375
, 1.0732421875
▁during 4.9140625
▁initial 3.5859375
▁clin 1.5087890625
ical 0.0007119178771972656
▁tri 0.1392822265625
als 0.0001214742660522461
. 0.3623046875
▁While 4.3046875
▁these 4.61328125
▁find 2.611328125
ings 0.00044274330139160156
▁have 2.330078125
▁gar 5.80078125
ner 0.0008873939514160156
ed 0.0002613067626953125
▁significant 2.181640625
▁attention 0.86279296875
▁among 3.845703125
▁research 4.81640625
ers 0.045257568359375
▁and 0.455078125
▁patients 3.7578125
▁al 0.55810546875
ike 0.0001087188720703125
, 0.0234832763671875
▁anal 1.1591796875
yst 0.0015077590942382812
s 0.0018033981323242188
▁are 1.4130859375
▁ur 0.82080078125
ging 0.00027942657470703125
▁ca 0.027099609375
ution 0.00010001659393310547
▁until 2.626953125
▁further 1.0673828125
▁data 1.1865234375
▁establish 8.921875
es 0.321533203125
▁its 2.314453125
▁safety 1.6083984375
▁and 0.08184814453125
▁effic 0.2481689453125
acy 0.0008039474487304688
. 0.27490234375
<0x0A> 0.06988525390625
The 1.2607421875
▁phase 4.27734375
▁ 0.962890625
1 0.08135986328125
▁clin 1.5546875
ical 0.00023365020751953125
▁trial 0.232421875
, 1.138671875
▁conducted 1.2197265625
▁on 2.052734375
▁a 3.779296875
▁small 0.5146484375
▁group 0.60498046875
▁of 0.0048370361328125
▁patients 0.469970703125
▁with 0.5458984375
▁advanced 0.7041015625
- 4.1171875
stage 0.007610321044921875
▁can 2.25390625
cers 0.0002875328063964844
▁such 2.060546875
▁as 0.0013341903686523438
▁lung 2.080078125
▁and 1.1142578125
▁o 2.16796875
var 0.03448486328125
ian 0.00029206275939941406
, 1.2802734375
▁showed 1.4755859375
▁that 0.716796875
▁M 0.7255859375
G 0.0018749237060546875
X 0.0003712177276611328
- 0.003971099853515625
1 0.001827239990234375
5 0.0002677440643310547
0 0.0002944469451904297
▁successfully 4.73828125
▁in 1.763671875
hib 0.00786590576171875
ited 0.05859375
▁tum 0.5302734375
or 0.591796875
▁growth 0.09918212890625
▁in 1.10546875
▁over 3.73828125
▁ 0.358642578125
6 2.00390625
0 0.166259765625
% 0.125244140625
▁of 0.00818634033203125
▁participants 1.615234375
. 0.378173828125
▁Moreover 3.1640625
, 0.000865936279296875
▁research 4.08984375
ers 0.01279449462890625
▁observed 0.9345703125
▁a 1.5576171875
▁reduction 2.380859375
▁in 0.058685302734375
▁the 1.673828125
▁size 0.505859375
▁of 0.08990478515625
▁tum 0.468994140625
ors 0.05633544921875
▁in 0.37158203125
▁ 1.349609375
4 1.86328125
0 0.61083984375
% 0.0313720703125
▁of 0.0202484130859375
▁the 2.15234375
▁patients 0.68017578125
, 1.048828125
▁mark 5.15625
ing 0.0003390312194824219
▁a 0.66455078125
▁potentially 4.75
▁significant 0.5615234375
▁adv 2.22265625
ancement 0.000270843505859375
▁in 0.1429443359375
▁the 0.7353515625
▁on 3.853515625
going 0.08978271484375
▁battle 0.74169921875
▁against 0.0101165771484375
▁cancer 0.10296630859375
. 0.01605224609375
<0x0A> 0.07965087890625
Dr 3.994140625
. 0.178955078125
▁Em 6.5859375
ily 0.818359375
▁Dav 5.94921875
ies 0.262451171875
, 0.0438232421875
▁the 1.7421875
▁lead 0.857421875
▁research 0.81201171875
er 0.0012722015380859375
▁at 2.00390625
▁Med 0.302001953125
Gen 0.00750732421875
, 0.09136962890625
▁expressed 1.6240234375
▁c 4.6796875
aut 0.00045418739318847656
ious 0.0004324913024902344
▁excitement 5.109375
▁about 1.365234375
▁the 0.26416015625
▁find 1.4404296875
ings 5.9604644775390625e-06
, 0.52490234375
▁stating 1.23828125
, 2.2109375
▁" 0.29345703125
Wh 2.5625
ile 0.050933837890625
▁the 2.58203125
▁initial 2.88671875
▁data 2.078125
▁from 2.16796875
▁the 1.9560546875
▁trial 1.357421875
▁is 0.434326171875
▁prom 0.57568359375
ising 7.486343383789062e-05
, 0.026214599609375
▁it 1.6025390625
▁is 0.272216796875
▁cru 3.2578125
cial 0.002475738525390625
▁to 0.92578125
▁remember 2.072265625
▁that 0.006145477294921875
▁this 0.79248046875
▁is 0.1448974609375
▁only 1.115234375
▁the 0.63330078125
▁first 0.63623046875
▁step 0.61376953125
. 2.4140625
▁We 0.626953125
▁need 0.99853515625
▁to 0.11309814453125
▁conduct 1.3798828125
▁further 0.62841796875
▁studies 1.3193359375
▁to 0.294677734375
▁fully 3.1484375
▁understand 0.67529296875
▁the 0.0751953125
▁drug 2.17578125
' 0.0272064208984375
s 5.364418029785156e-05
▁mechan 5.90234375
isms 0.005420684814453125
▁and 1.1083984375
▁confirm 4.67578125
▁its 0.036895751953125
▁safety 0.307373046875
▁and 0.311767578125
▁effic 0.0955810546875
acy 4.863739013671875e-05
▁profile 6.5703125
." 0.56103515625
<0x0A> 0.0286712646484375
The 2.318359375
▁experimental 4.21484375
▁drug 0.405517578125
▁functions 4.703125
▁by 0.1617431640625
▁target 1.06640625
ing 0.00045228004455566406
▁a 0.8837890625
▁specific 0.99658203125
▁protein 0.751953125
▁linked 5.80859375
▁to 0.0218505859375
▁the 1.8173828125
▁growth 0.63134765625
▁and 0.398681640625
▁spread 0.28076171875
▁of 0.003963470458984375
▁cancer 0.2457275390625
▁cells 0.06683349609375
. 0.474365234375
▁By 0.970703125
▁in 0.68212890625
hib 0.0008463859558105469
iting 0.00010418891906738281
▁this 0.22412109375
▁protein 0.032470703125
, 0.07958984375
▁M 0.2049560546875
G 0.0006780624389648438
X 0.000762939453125
- 0.0007495880126953125
1 0.0004029273986816406
5 0.0001093149185180664
0 2.5510787963867188e-05
▁a 2.517578125
ims 0.009765625
▁to 0.0002079010009765625
▁prevent 1.6435546875
▁the 0.96923828125
▁cells 4.40234375
▁from 0.014007568359375
▁pro 2.447265625
l 7.95125961303711e-05
ifer 0.0001424551010131836
ating 0.0013093948364257812
▁and 0.276123046875
▁met 1.97265625
ast 0.0008001327514648438
as 0.005695343017578125
izing 0.00894927978515625
, 0.43505859375
▁offering 2.4296875
▁potential 2.806640625
▁hope 1.4306640625
▁for 0.68212890625
▁patients 0.417724609375
▁in 4.65625
▁advanced 2.421875
▁stages 0.15283203125
▁of 0.06353759765625
▁their 4.09765625
▁disease 0.375732421875
. 0.0244598388671875
<0x0A> 0.0718994140625
Des 1.2939453125
p 0.0003597736358642578
ite 5.0067901611328125e-06
▁the 0.36181640625
▁initial 2.533203125
▁success 1.2001953125
▁of 1.0703125
▁M 1.34765625
G 0.00028133392333984375
X 0.0013914108276367188
- 0.0004482269287109375
1 0.00025725364685058594
5 0.0001741647720336914
0 0.0003666877746582031
, 0.094482421875
▁exper 2.310546875
ts 2.276897430419922e-05
▁are 1.62890625
▁rem 5.38671875
inding 0.00383758544921875
▁the 0.69140625
▁public 0.06719970703125
▁that 0.46484375
▁clin 1.9248046875
ical 0.00022029876708984375
▁tri 0.035552978515625
als 1.9431114196777344e-05
▁are 0.48095703125
▁a 2.369140625
▁length 1.3173828125
y 0.0001500844955444336
▁and 0.50390625
▁met 4.37890625
icul 0.0001049041748046875
ous 0.0021953582763671875
▁process 0.005664825439453125
. 1.015625
▁Dr 2.556640625
. 0.0013608932495117188
▁Laura 5.7421875
▁Roberts 6.76171875
, 0.0638427734375
▁a 0.257080078125
▁prominent 3.484375
▁on 0.2354736328125
colog 0.052734375
ist 0.0010919570922851562
▁at 0.90234375
▁St 2.76953125
. 0.121826171875
▁George 1.599609375
' 0.033721923828125
s 6.783008575439453e-05
▁Hospital 0.338623046875
▁in 0.9814453125
▁London 0.023284912109375
, 0.0047760009765625
▁emphas 0.6923828125
izes 1.248046875
▁the 0.75634765625
▁need 1.056640625
▁for 0.08514404296875
▁vig 6.625
il 0.005397796630859375
ance 0.10528564453125
. 3.578125
▁" 0.2529296875
Wh 0.7412109375
ile 0.0002551078796386719
▁these 1.1513671875
▁pre 3.505859375
lim 0.0015573501586914062
inary 2.5510787963867188e-05
▁results 0.859375
▁are 0.0784912109375
▁encourag 0.39990234375
ing 2.396106719970703e-05
, 0.003986358642578125
▁it 0.66162109375
▁is 0.25146484375
▁important 1.6376953125
▁to 0.130859375
▁recognize 3.203125
▁that 0.031829833984375
▁we 2.39453125
▁must 2.123046875
▁proceed 1.7578125
▁with 0.312255859375
▁ca 0.031158447265625
ution 4.5299530029296875e-06
▁and 1.46875
▁wait 4.02734375
▁until 3.5390625
▁we 1.7763671875
▁have 0.2451171875
▁access 6.1796875
▁to 0.0014581680297851562
▁more 0.46044921875
▁data 1.64453125
▁from 2.5
▁larger 0.98828125
- 3.224609375
scale 0.002635955810546875
▁tri 0.615234375
als 1.0728836059570312e-06
," 1.8798828125
▁she 0.1158447265625
▁said 0.8955078125
. 0.035980224609375
<0x0A> 0.122314453125
The 1.8544921875
▁bi 4.61328125
ote 0.046966552734375
ch 0.0567626953125
▁industry 0.86279296875
▁has 0.93603515625
▁experienced 2.251953125
▁previous 10.5859375
▁instances 3.19921875
▁where 2.50390625
▁prom 1.6396484375
ising 0.00010716915130615234
▁dru 1.2568359375
gs 1.6689300537109375e-06
▁have 1.0908203125
▁fal 5.38671875
tered 0.0008440017700195312
▁during 1.314453125
▁later 1.3427734375
▁stages 0.5263671875
▁of 0.04376220703125
▁clin 0.42919921875
ical 8.988380432128906e-05
▁tri 0.11822509765625
als 8.71419906616211e-05
. 0.55859375
▁The 3.365234375
▁path 8.625
▁to 0.468505859375
▁commercial 3.119140625
ization 0.2440185546875
▁is 0.703125
▁often 1.6650390625
▁imp 10.2421875
eded 0.0197906494140625
▁by 0.0266571044921875
▁un 2.66015625
for 0.20703125
ese 7.95125961303711e-05
en 0.0037212371826171875
▁comp 1.978515625
lications 0.001239776611328125
, 0.85595703125
▁such 1.8662109375
▁as 0.00013136863708496094
▁unf 4.015625
avor 0.0038547515869140625
able 0.0001531839370727539
▁side 0.362060546875
▁effects 0.01171112060546875
▁or 0.2236328125
▁lack 2.576171875
l 2.005859375
uster 0.0030422210693359375
▁performance 2.794921875
▁in 0.79443359375
▁larger 1.419921875
▁patient 0.892578125
▁populations 0.402587890625
. 0.0210113525390625
▁Con 5.55859375
sequently 0.030609130859375
, 6.866455078125e-05
▁many 3.05078125
▁prom 5.71875
ising 0.00033211708068847656
▁ther 1.8388671875
ap 9.226799011230469e-05
ies 6.9141387939453125e-06
▁fail 1.4404296875
▁to 0.0693359375
▁gain 3.322265625
▁necessary 8.5234375
▁appro 0.98876953125
val 2.2411346435546875e-05
s 1.005859375
▁for 1.671875
▁bro 4.94140625
ader 0.0001227855682373047
▁use 0.248291015625
. 0.64697265625
<0x0A> 0.0472412109375
Anal 3.59765625
yst 0.01113128662109375
s 0.0185394287109375
▁echo 6.40234375
▁the 1.583984375
▁c 3.91796875
aut 0.00019419193267822266
ious 0.005290985107421875
▁optim 0.1658935546875
ism 0.00016236305236816406
▁exhib 4.34765625
ited 0.0005240440368652344
▁by 0.00376129150390625
▁medical 2.625
▁exper 0.70751953125
ts 1.1920928955078125e-06
. 1.18359375
▁" 2.5
Wh 0.3955078125
ile 0.00011873245239257812
▁initial 4.0859375
▁data 1.86328125
▁suggests 2.66796875
▁potential 2.8671875
, 3.26171875
▁it 1.146484375
▁would 5.06640625
▁be 0.0117950439453125
▁impr 3.373046875
udent 0.00022840499877929688
▁to 0.0163726806640625
▁over 1.5830078125
look 2.15625
▁the 0.11724853515625
▁hur 4.55078125
d 1.4066696166992188e-05
les 0.0011129379272460938
▁still 2.857421875
▁facing 2.248046875
▁M 1.1298828125
G 0.0007715225219726562
X 0.00044083595275878906
- 0.0009379386901855469
1 0.0004863739013671875
5 0.0001652240753173828
0 0.00019538402557373047
," 0.481201171875
▁commented 3.416015625
▁Rach 6.71484375
el 0.12261962890625
▁Wilson 4.7578125
, 0.167236328125
▁a 0.54150390625
▁ph 2.201171875
arma 0.034759521484375
ce 0.0251617431640625
ut 0.00011014938354492188
ical 0.0006799697875976562
▁industry 1.552734375
▁anal 0.491943359375
yst 1.5020370483398438e-05
▁at 0.342041015625
▁Bern 6.25390625
stein 0.053924560546875
. 1.0712890625
▁" 0.1507568359375
It 2.45703125
▁is 0.2249755859375
▁cru 1.3173828125
cial 0.00016129016876220703
▁to 0.425537109375
▁not 6.12890625
▁get 1.2431640625
▁carried 1.9921875
▁away 0.00010263919830322266
▁until 2.943359375
▁more 1.7421875
▁compreh 2.28515625
ensive 0.00032639503479003906
▁clin 2.705078125
ical 8.189678192138672e-05
▁trial 2.3125
▁results 0.7119140625
▁are 0.385986328125
▁available 0.505859375
." 0.29052734375
<0x0A> 0.0277099609375
Med 2.39453125
Gen 0.0274658203125
, 1.673828125
▁a 3.1015625
▁relatively 1.9794921875
▁small 0.64208984375
▁bi 0.56591796875
ote 0.01204681396484375
ch 0.028961181640625
▁firm 0.363037109375
, 0.6240234375
▁has 0.9931640625
▁seen 4.0625
▁its 0.2103271484375
▁stock 0.57763671875
▁so 2.619140625
ar 0.0099945068359375
▁in 0.7666015625
▁recent 0.64208984375
▁days 0.8525390625
▁as 1.955078125
▁news 2.205078125
▁of 0.0196990966796875
▁M 2.291015625
G 0.00042700767517089844
X 0.0006709098815917969
- 0.0008449554443359375
1 0.0002875328063964844
5 0.0001480579376220703
0 0.0001926422119140625
' 0.119873046875
s 0.0002665519714355469
▁initial 3.197265625
▁success 0.6015625
▁spread 0.69482421875
. 1.46484375
▁However 1.3125
, 0.00013935565948486328
▁financial 4.1171875
▁anal 0.81982421875
yst 0.00014281272888183594
s 0.08905029296875
▁warn 1.6943359375
▁that 0.63134765625
▁this 2.45703125
▁spec 6.55859375
ulative 0.1561279296875
▁enthus 3.013671875
ias 8.83340835571289e-05
m 8.571147918701172e-05
▁may 0.83544921875
▁be 0.97509765625
▁prem 0.384033203125
ature 1.6689300537109375e-05
. 0.3935546875
▁A 5.9296875
▁single 6.19921875
▁prom 2.666015625
ising 0.0002472400665283203
▁drug 1.0810546875
▁is 1.908203125
▁far 4.3046875
▁from 0.01161956787109375
▁a 1.0322265625
▁guaranteed 3.251953125
▁path 2.994140625
way 1.6025390625
▁to 0.041107177734375
▁commercial 1.46484375
▁success 0.71630859375
, 0.72900390625
▁and 0.417724609375
▁the 1.986328125
▁current 5.1796875
▁excitement 4.09765625
▁may 0.91015625
▁actually 7.8984375
▁h 2.0546875
inder 0.0007767677307128906
▁Med 2.7734375
Gen 0.005031585693359375
' 0.039794921875
s 3.123283386230469e-05
▁ability 0.953125
▁to 0.00015354156494140625
▁secure 1.80859375
▁further 2.2578125
▁fund 0.32080078125
ing 0.00014448165893554688
▁to 4.17578125
▁ensure 5.62890625
▁the 0.76171875
▁drug 0.70751953125
' 0.14013671875
s 1.5020370483398438e-05
▁development 1.654296875
. 0.440673828125
<0x0A> 0.10614013671875
Des 2.080078125
p 0.00046706199645996094
ite 1.5616416931152344e-05
▁the 0.81298828125
▁c 3.6484375
aut 0.0025691986083984375
ious 0.00920867919921875
▁sentiment 5.66796875
, 0.7783203125
▁many 1.4716796875
▁cancer 2.59765625
▁patients 0.08319091796875
▁and 0.56591796875
▁their 0.216796875
▁families 0.2408447265625
▁are 0.9443359375
▁hoping 3.4765625
▁that 1.1435546875
▁M 0.286865234375
G 0.0001958608627319336
X 0.0004343986511230469
- 0.0004432201385498047
1 0.0002104043960571289
5 6.914138793945312e-05
0 4.267692565917969e-05
▁will 0.63232421875
▁eventually 2.677734375
▁offer 2.982421875
▁a 0.70654296875
▁treatment 5.1796875
▁option 0.0953369140625
▁for 1.2861328125
▁those 0.82666015625
▁batt 3.13671875
ling 0.00017309188842773438
▁this 2.04296875
▁dead 1.7529296875
ly 0.00011861324310302734
▁disease 0.0249481201171875
. 0.00556182861328125
▁Med 4.921875
Gen 0.0037212371826171875
▁plans 3.091796875
▁to 0.00661468505859375
▁initi 2.1640625
ate 3.457069396972656e-05
▁further 2.55078125
▁tri 1.5400390625
als 1.1563301086425781e-05
▁involving 4.21875
▁larger 0.442138671875
▁patient 0.373046875
▁groups 2.03125
▁next 7.00390625
▁year 0.01861572265625
, 0.29638671875
▁int 8.609375
ending 0.0007662773132324219
▁to 0.00433349609375
▁provide 2.865234375
▁a 1.9443359375
▁more 0.78857421875
▁compreh 0.469970703125
ensive 8.296966552734375e-05
▁understanding 1.58984375
▁of 0.0014600753784179688
▁the 0.113525390625
▁drug 0.036712646484375
' 0.00992584228515625
s 3.2782554626464844e-05
▁potential 1.3984375
▁benefits 2.19921875
▁and 0.1168212890625
▁side 3.681640625
▁effects 0.00787353515625
. 0.0133819580078125
<0x0A> 0.299560546875
The 2.171875
▁road 4.73046875
▁to 0.4501953125
▁finding 2.724609375
▁effective 1.37890625
▁cancer 0.77490234375
▁treat 0.169677734375
ments 7.510185241699219e-06
▁is 0.62353515625
▁long 0.84765625
▁and 0.11798095703125
▁ar 0.72119140625
du 6.210803985595703e-05
ous 7.510185241699219e-06
, 0.1842041015625
▁but 1.0654296875
▁the 0.93701171875
▁early 2.953125
▁signs 1.3349609375
▁of 0.6611328125
▁progress 1.7607421875
▁demonstrated 4.80859375
▁by 0.004558563232421875
▁Med 3.322265625
Gen 0.0010271072387695312
' 0.71875
s 6.175041198730469e-05
▁M 0.53759765625
G 0.0003864765167236328
X 0.00024056434631347656
- 0.0004718303680419922
1 0.0002300739288330078
5 0.00010716915130615234
0 9.85860824584961e-05
▁are 0.951171875
▁und 3.197265625
ou 0.450927734375
bt 0.0002351999282836914
edly 0.00017762184143066406
▁worth 4.875
▁acknowled 4.73828125
ging 0.01349639892578125
. 0.185791015625
▁As 1.11328125
▁the 0.97509765625
▁scientific 3.603515625
▁community 0.02410888671875
▁eager 4.6796875
ly 1.6927719116210938e-05
▁a 0.058258056640625
wa 6.67572021484375e-06
its 1.1920928955078125e-07
▁more 1.66796875
▁extensive 3.474609375
▁results 3.0
, 0.7705078125
▁anal 4.7109375
yst 0.0001977682113647461
s 0.0004925727844238281
, 4.35546875
▁research 2.1484375
ers 0.0004589557647705078
, 0.01381683349609375
▁and 0.01207733154296875
▁patients 0.239013671875
▁are 3.966796875
▁rem 2.796875
ind 0.10345458984375
ed 6.592273712158203e-05
▁that 1.4345703125
▁the 2.146484375
▁journey 1.30859375
▁to 1.046875
▁a 1.638671875
▁vi 3.1171875
able 3.814697265625e-05
▁cancer 0.7001953125
▁drug 3.3359375
▁is 0.5517578125
▁one 2.626953125
▁that 0.517578125
▁dem 3.30078125
ands 9.5367431640625e-07
▁p 0.52197265625
atience 0.0004334449768066406
, 0.64794921875
▁pers 1.8330078125
istence 0.0004398822784423828
, 0.0032405853271484375
▁and 0.00026607513427734375
▁res 4.58984375
ili 0.03253173828125
ence 1.0728836059570312e-06
. 0.1553955078125
